The Vectra test is moderately accurate at measuring rheumatoid arthritis disease activity, consistently outperforming standard single-marker blood tests like CRP but falling short of a perfect measure. Its correlation with established clinical disease activity scores sits around 0.51, which means it captures a meaningful portion of what’s happening in your joints but doesn’t tell the whole story on its own. It works best as one piece of a larger clinical picture rather than a standalone answer.
What the Vectra Test Actually Measures
Unlike a simple CRP or sed rate test that looks at one marker of inflammation, the Vectra test measures 12 different proteins in your blood. These include markers of inflammation (CRP, IL-6, SAA), cartilage and bone breakdown (MMP-1, MMP-3, YKL-40), blood vessel growth tied to inflamed tissue (VEGF-A, EGF), immune cell activation (TNF-RI, VCAM-1), and metabolic signals (leptin, resistin). An algorithm combines all 12 into a single score from 1 to 100.
Scores break into three categories: low disease activity (under 30), moderate (30 to 44), and high (above 44). The current version uses a leptin-adjusted calculation, which helps account for the fact that body fat can raise some of these protein levels independent of RA activity.
How Well It Tracks Disease Activity
The Vectra score correlates with all the major clinical disease activity tools rheumatologists use, including DAS28-CRP, DAS28-ESR, SDAI, and CDAI. That correlation holds for both seropositive and seronegative RA, which matters because seronegative patients often have fewer reliable lab markers to track.
Where the test shows a clear edge over CRP alone is in discriminating treatment responders from non-responders. In one study, the change in Vectra score had an AUROC of 0.77 for identifying patients who responded to treatment based on DAS28-CRP criteria, compared to 0.68 for CRP alone. For identifying patients who achieved at least a 50% improvement in symptoms, the Vectra score’s AUROC was 0.69 versus 0.59 for CRP. That gap is statistically significant. In plain terms, if you lined up a responder and a non-responder, the Vectra score would correctly identify who responded about 69 to 77% of the time, depending on which response criteria you use. CRP alone gets it right closer to 59 to 68% of the time.
Perhaps the most interesting finding comes from MRI data. In one analysis, the amount of joint inflammation visible on MRI (synovitis and bone marrow swelling) correlated significantly with the Vectra score but not with DAS28-CRP. This suggests the test may pick up on subclinical inflammation that traditional assessments miss.
Tracking Treatment Response
The test can detect changes in disease activity quickly after starting a biologic. In a study of patients starting a TNF inhibitor, the Vectra score dropped significantly within just two weeks of treatment. That speed matters because it can take months for clinical symptoms to fully shift, and knowing early whether a medication is working can guide treatment decisions.
At 14 weeks, patients who achieved a strong clinical response had significantly lower Vectra scores than non-responders. However, by 24 weeks that statistical difference between responders and non-responders faded, which hints at a limitation: the test may be better at capturing early treatment effects than long-term outcomes. This inconsistency is one reason rheumatologists don’t rely on the score in isolation.
Where the Test Falls Short
A correlation of 0.51 with DAS28-CRP means the Vectra score explains roughly a quarter of the variability in clinical disease activity. The rest comes from factors the blood test can’t capture: pain perception, joint tenderness on exam, functional limitations, and other sources of inflammation unrelated to RA. Infections, obesity, and other inflammatory conditions can push scores higher without reflecting a true RA flare.
The leptin adjustment in the current version partially addresses the obesity issue, but no blood test can fully separate RA-specific inflammation from other sources. A high score in someone with an active infection or significant obesity might overstate their RA activity, while a patient with primarily mechanical joint damage and little active inflammation could score low despite significant symptoms.
No major medical society currently recommends the Vectra test as a required part of RA management. It remains an optional tool, most useful when clinical assessments are ambiguous or when a rheumatologist wants an objective benchmark to compare over time.
Cost and Availability
The Vectra test is commercially available through Myriad Genetics and run under CLIA laboratory standards. Medicare covers it and has reimbursed the test since October 2015, with a recommended limit of two tests per patient per year. Private insurance coverage varies, so checking with your plan before ordering is worthwhile. If your rheumatologist orders it, you’ll get a simple blood draw, and results typically include your numerical score along with the low, moderate, or high classification.
What the Score Means for You
If your Vectra score is low and your symptoms are well controlled, that’s reassuring confirmation that your current treatment is working at the molecular level. A high score alongside worsening symptoms strengthens the case for adjusting your medication. The trickier scenario is a mismatch: feeling fine but scoring high, or feeling terrible with a low score. In those cases, the test is one data point your rheumatologist weighs against joint exams, imaging, and your own symptom reports.
The test is most valuable when tracked over time rather than interpreted as a single snapshot. A score of 55 dropping to 28 after starting a new biologic tells a clearer story than a single reading of 40 with no context. If your rheumatologist orders it periodically, the trend line matters more than any individual number.